Akorn acquires Betimol from Santen, to add $0.03-$0.04 in EPS in 2014


Akorn (AKRX -0.3%) acquires the NDA and all rights to Betimol 0.25% and 0.5%, a prescription eye drop medicine for ocular hypertension/glaucoma, from Santen. It plans to begin shipment in Q1.

Betimol is expected to add $0.03-$0.04 in EPS on $8M-$9M in revenue in 2014.

Previous: Akorn acquires eye drop solutions from Merck in $52.8M deal

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs